Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation

Parasites and Vectors

Volumn 5, Issue 1, 2012, Pages

  Passero, Luiz Felipe D ^a,b   Carvalho, Ana Kely ^a   Bordon, Maria Lac ^a   Bonfim Melo, Alexis ^b   Carvalho, Karina ^c   Kallás, Esper G ^c   Santos, Bianca Ba ^c   Toyama, Marcos H ^b   Paes Leme, Adriana ^d   Corbett, Carlos Ep ^a   Laurenti, Márcia D ^a  

^a Depto de Patologia   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

Cellular immune response; Immunization; Leishmania (Viannia) shawi; Long term protection; Proteic fraction

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; LEISHMANIA (VIANNIA) SHAWI ANTIGEN; PARASITE ANTIGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIA (VIANNIA) SHAWI; MALE; MEMORY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PARASITE LOAD; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEISHMANIASIS; SECRETION;

LEISHMANIA SHAWI; MUS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA; LEISHMANIASIS; MALE; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; TH1 CELLS;

EID: 84859050286     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-5-64     Document Type: Article

References (55)

1. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE, Parasite Immunol 2009 31 423 431 10.1111/j.1365-3024.2009.01116.x 19646206
2. A cross-sectional study on the clinical and immunological spectrum of human Leishmania (L.) infantum chagasi infection in the Brazilian Amazon region. Crescente JA, Silveira FT, Lainson R, Gomes CM, Laurenti MD, Corbett CE, Trans R Soc Trop Med Hyg 2009 103 1250 1256 10.1016/j.trstmh.2009.06.010 19615710
3. Leishmania (Viannia) braziliensis is the prevalent species infecting patients with tegumentary leishmaniasis from Mato Grosso State, Brazil. Carvalho Mde L, de Andrade AS, Fontes CJ, Hueb M, De Oliveira Silva S, Melo MN, Acta Trop 2006 98 277 285 10.1016/j.actatropica.2006.06.001 16846569 (Pubitemid 44066287)
4. Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B. Morrison B, Mendoza I, Delgado D, Reyes Jaimes O, Aranzazu N, Paniz Mondolfi AE, Clin Exp Dermatol 2010 35 116 9 10.1111/j.1365-2230.2009.03737.x 19886959
5. Cutaneous leishmaniasis of man due to Leishmania (Viannia) shawi Lainson, de Souza, Pávoa, Ishikawa & Silveira, in Pará State, Brazil. Shaw JJ, Ishikawa EA, Lainson R, Braga RR, Silveira FT, Ann Parasitol Hum Comp 1991 66 243 246 1822654
6. Epidemiology and ecology of leishmaniasis in Latin-America. Lainson R, Shaw JJ, Nature 1978 273 595 600 10.1038/273595a0 351409 (Pubitemid 8352537)
7. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F, Vaccine 2005 23 3642 3648 10.1016/j.vaccine.2005.02.015 15882524 (Pubitemid 40692409)
8. Ensaio sobre a vacinação preventiva na leishmaniose tegumentar americana, com germes mortos. Pessoa SB, Pestana BR, Rev Biol Hyg 1940 10 112 118
9. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Antunes CM, Mayrink W, Magalhães PA, Costa A, Melo MN, Dias M, Michalick MSM, Williams P, Lima AO, Vieira JBF, Schettini APM, Int J Epidemiol 1986 15 572 580 10.1093/ije/15.4.572 3546170 (Pubitemid 17229495)
10. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Palatnik-de-Sousa CB, Paraguai-de-Souza E, Gomes EM, Borojevic R, Braz J Med Biol Res 1994 27 547 551 8081280
11. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Masih S, Arora SK, Vasishta RK, Exp Parasitol 2011 129 55 64 10.1016/j.exppara.2011.05.014 21640106
12. The cellular immune response to a purified antigen from Leishmania mexicana subsp. amazonensis enhances the size of the leishmanial lesion on susceptible mice. Rodrigues MM, Mendonça-Previato L, Charlab R, Barcinski MA, Infect Immun 1987 55 3142 3148 3500131 (Pubitemid 18008290)
13. Gene therapy targeting hematopoietic cells: better not leave it to chance. Baum C, von Kalle C, Acta Haematol 2003 110 107 119 10.1159/000072459 14583670 (Pubitemid 37340189)
14. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C, Vaccine 2009 27 3505 3512 10.1016/j.vaccine.2009.03.045 19464528
15. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G, Vaccine 2005 23 2825 2840 10.1016/j.vaccine.2004.11.061 15780731 (Pubitemid 40386484)
16. Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes. Passero LF, Marques C, Vale-Gato I, Corbett CE, Laurenti MD, Santos-Gomes G, Arch Dermatol Res 2012 304 47 55 10.1007/s00403-011-1171-7 21882046
17. One Health: the global challenge of epidemic and endemic leishmaniasis. Palatnik-de-Sousa CB, Day MJ, Parasit Vectors 2011 4 197 10.1186/1756-3305-4-197 21985335
18. Protection of C57BL/10 mice by vaccination with association of purified proteins from Leishmania (Leishmania) amazonensis. Mora AM, Mayrink W, Costa RT, Costa CA, Genaro O, Nascimento E, Rev Inst Med Trop Sao Paulo 1999 41 243 248 10564919
19. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan. Pinheiro RO, Pinto EF, de Matos Guedes HL, Filho OA, de Mattos KA, Saraiva EM, de Mendonça SC, Rossi-Bergmann B, Vaccine 2006 24 5645 5652 10.1016/j.vaccine.2006.03.023 16621179 (Pubitemid 43867099)
20. Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice. Gorczynski RM, Cell Immunol 1985 94 1 10 10.1016/0008-8749(85) 90080-2 3160485 (Pubitemid 15247790)
21. The inflammatory response promotes cutaneous metastasis in hamsters infected with Leishmania (Viannia) panamensis. Travi BL, Osorio Y, Saravia NG, J Parasitol 1996 82 454 457 8636852 (Pubitemid 26172545)
22. Ex vivo and in vivo biological behavior of Leishmania (Viannia) shawi. Passero LF, Sacomori JV, Tomokane TY, Corbett CE, da Silveira FT, Laurenti MD, Parasitol Res 2009 105 1741 1747 10.1007/s00436-009-1614-7 19756748
23. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D, PLoS Negl Trop Dis 2011 5 1204 10.1371/journal.pntd.0001204 21695103
24. Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms. Passero LF, Da Costa Bordon ML, De Carvalho AK, Martins LM, Corbett CE, Laurenti MD, APMIS 2010 118 973 981 10.1111/j.1600-0463.2010.02679.x 21091779
25. A general classification of New World Leishmania using numerical zymotaxonomy. Cupolillo E, Grimaldi G Jr, Momen H, Am J Trop Med Hyg 1994 50 296 311 8147488 (Pubitemid 24110481)
26. Isolation of a new L-amino acid oxidase from Crotalus durissus cascavella venom. Toyama MH, Toyama DO, Passero LF, Laurenti MD, Corbett CE, Tomokane TY, Fonseca FV, Antunes E, Joazeiro PP, Beriam LO, Martins MA, Monteiro HS, Fonteles MC, Toxicon 2006 47 47 57 10.1016/j.toxicon.2005.09.008 16307769 (Pubitemid 43042395)
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Laemmli UK, Nature 1970 227 680 685 10.1038/227680a0 5432063
28. Comparison of proteins expressed by Pseudomonas aeruginosa strains representing initial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography-tandem mass spectrometry. Hanna SL, Sherman NE, Kinter MT, Goldberg JB, Microbiology 2000 146 2495 2508 11021925
29. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA, J Exp Med 2002 195 1565 1573 10.1084/jem.20020147 12070284 (Pubitemid 34666070)
30. Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi. Passero LF, Marques C, Vale-Gato I, Corbett CE, Laurenti MD, Santos-Gomes G, Parasitol Int 2010 59 159 165 10.1016/j.parint. 2009.12.010 20060062
31. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. Ahmed SA, Gogal RM Jr, Walsh JE, J Immunol Methods 1994 170 211 224 10.1016/0022-1759(94)90396-4 8157999 (Pubitemid 24122510)
32. + lymphocyte subsets in hepatic and splenic tissues during murine visceral leishmaniasis. Gomes-Pereira S, Rodrigues OR, Santos-Gomes GM, Immunol Lett 2004 95 63 70 10.1016/j.imlet.2004.06.005 15325799 (Pubitemid 39119901)
33. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, Almeida R, Peacock CS, McCann S, Blackwell JM, Vaccine 2006 24 2602 2616 10.1016/j.vaccine.2005.12.012 16406227 (Pubitemid 43290392)
34. Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences. Rey-Ladino JA, Joshi PB, Singh B, Gupta R, Reiner NE, Exp Parasitol 1997 85 249 263 10.1006/expr.1996.4137 9085922 (Pubitemid 27246118)
35. Kinesin motor domain of Leishmania donovani as a future vaccine candidate. Dey A, Sharma P, Redhu NS, Singh S, Clin Vaccine Immunol 2008 15 836 842 10.1128/CVI.00433-07 18353921 (Pubitemid 351967025)
36. Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis. Dey A, Kumar U, Sharma P, Singh S, Vaccine 2009 27 5152 5160 10.1016/j.vaccine.2009.05.100 19559111
37. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U, Kloetzel PM, Immunol Rev 2005 207 19 30 10.1111/j.0105-2896.2005.00308.x 16181324 (Pubitemid 41415005)
38. The IL-4 receptor: signaling mechanisms and biologic functions. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE, Annu Rev Immunol 1999 17 701 738 10.1146/annurev.immunol.17.1.701 10358772 (Pubitemid 29241138)
39. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Beyrodt CG, Pinto AR, Freymüller E, Barbiéri CL, Infect Immun 1997 65 2052 2059 9169731 (Pubitemid 27237277)
40. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8 T-cell responses. Stäger S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM, Nat Med 2003 9 1287 1292 10.1038/nm933 14502281 (Pubitemid 37279852)
41. IL-4-secreting CD4 T cells are crucial to the development of CD8 T-cell responses against malaria liver stages. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F, Nat Med 2002 8 166 170 10.1038/nm0202-166 11821901 (Pubitemid 34155128)
42. Potential role for interleukin-10 in the immunosuppression associated with kalaazar. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa Ade A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM, J Clin Invest 1993 92 2626 2632 10.1172/JCI116878 8254019 (Pubitemid 24006526)
43. Leishmania major: Secreted antigens of Leishmania major promastigotes shift the immune response of the C57BL/6 mice toward Th2 in vitro. Tabatabaee PA, Abolhassani M, Mahdavi M, Nahrevanian H, Azadmanesh K, Exp Parasitol 2011 127 46 51 10.1016/j.exppara.2010.06.033 20603118
44. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. Whitmire JK, Tan JT, Whitton JL, J Exp Med 2005 201 1053 1059 10.1084/jem.20041463 15809350 (Pubitemid 40524673)
45. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Sprent J, Surh CD, Nat Immunol 2011 12 478 484 21739670
46. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL, J Exp Med 1994 179 589 600 10.1084/jem.179.2.589 7905019
47. Adhesion molecule expression patterns indicate activation and recruitment of CD4+ T cells from the lymph node to the peripheral blood of early cutaneous leishmaniasis patients. Costa RP, Gollob KJ, Machado PR, Bacellar OA, Almeida RP, Barral A, Barral-Netto M, Carvalho EM, Dutra WO, Immunol Lett 2003 90 155 159 10.1016/j.imlet.2003.09.001 14687718 (Pubitemid 37553142)
48. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. Croft M, Carter L, Swain SL, Dutton RW, J Exp Med 1994 180 1715 1728 10.1084/jem.180.5.1715 7525836 (Pubitemid 24328563)
49. Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. Freitas do Rosário AP, Muxel SM, Rodríguez-Málaga SM, Sardinha LR, Zago CA, Castillo-Méndez SI, Alvarez JM, D'Império Lima MR, J Immunol 2008 181 8344 8355 19050251
50. Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Stefani MM, Müller I, Louis JA, Eur J Immunol 1994 24 746 752 10.1002/eji.1830240338 7510243 (Pubitemid 24076644)
51. CD8 cytotoxic T cells in cutaneous leishmaniasis. Ruiz JH, Becker I, Parasite Immunol 2007 29 671 678 10.1111/j.1365-3024.2007.00991.x 18042173 (Pubitemid 350179394)
52. Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Colmenares M, Kima PE, Samoff E, Soong L, McMahon-Pratt D, Infect Immun 2003 71 3172 3182 10.1128/IAI.71.6.3172-3182.2003 12761096 (Pubitemid 36637540)
53. Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells. Herath S, Kropf P, Müller I, Parasite Immunol 2003 25 559 567 10.1111/j.0141-9838.2004.00668.x 15053777 (Pubitemid 38445399)
54. Interleukins, from 1 to 37, and interferon-: Receptors, functions, and roles in diseases. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA, Akdis CA, J Allergy Clin Immunol 2011 127 701 721 Akdis et al 2011 10.1016/j.jaci.2010.11.050 21377040
55. Mechanism and regulation of immunoglobulin isotype switching. Coffman RL, Lebman DA, Rothman P, Adv Immunol 1993 54 229 270 8379463 (Pubitemid 23289254)